ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Immatics

Status and phase: Enrolling; Phase 2; Phase 1

Conditions: Recurrent Cancer; Solid Tumor, Adult; Refractory Cancer; Cancer

Treatments: Device: IMADetect®; Biological: IMA203 product- flat dose; Biological: IMA203 Product; Drug: Nivolumab; Biological: IMA203CD8 Product

Study type: Interventional

Funder types: Industry

Identifiers

NCT03686124

IMA203-101

Details and patient eligibility

About

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

Full description

SCREENING: Patient eligibility will be determined by protocol inclusion/exclusion criteria including HLA (human leukocyte antigen) screening and a biopsy (or collection of archival tumor tissue) for biomarker screening. If the patient is eligible, white blood cells will be taken during leukapheresis for the manufacture of IMA203 or IMA203CD8 product.

MANUFACTURING: IMA203 or IMA203CD8 products will be made from the patients' white blood cells.

TREATMENT: Lymphodepletion with cyclophosphamide and fludarabine will occur in the days before the IMA203/IMA203CD8 product infusion to improve the duration of time that IMA203/IMA203CD8 product stays in the body. The patient will be admitted to the hospital during the T-cell infusion.

After the IMA203/IMA203CD8 product infusion, if applicable, a low dose of IL-2 will be given subcutaneously until day 10.

In Extension Cohort B (IMA203) nivolumab will be administered intravenously.

Patients will be monitored closely throughout the study. The follow-up phase ends 5 years post infusion.

Enrollment: 375 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must have recurrent/progressing and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatment.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• HLA-A*02:01 positive
• For patients with ovarian/fallopian tube cancer only: Patients must have confirmed diagnosis of high-grade serous or endometrioid epithelial ovarian cancer (EOC), primary peritoneal cancer, or fallopian tube cancer.
• For patients with endometrial carcinoma only: Patients must have a histologically confirmed diagnosis of recurrent or persistent endometrial carcinoma.
• Measurable disease according to RECIST 1.1
• Adequate selected organ function per protocol
• Patient's tumor must express tumor antigen by "IMADetect® RT-qPCR. Retrospective testing will be required for patients that qualify.
• Life expectancy more than 5 months
• Female patient of childbearing potential must use adequate contraception prior to study entry until 12 months after the infusion of IMA203/IMA203CD8
• Male patient must agree to use effective contraception or be abstinent while on study and for 6 months after the infusion of IMA203/IMA203CD8
• The patient must have recovered from any side effects of prior therapy to Grade 1 or lower prior to lymphodepletion.

Exclusion criteria

• History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years
• Pregnant or breastfeeding
• Serious autoimmune disease Note: At the discretion of the investigator, these patients may be included if their disease is well controlled without the use of immunosuppressive agents.
• History of cardiac conditions as per protocol
• Prior stem cell transplantation or solid organ transplantation
• Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
• History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician
• Positive for HIV infection or with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.
• Patients with LDH greater than 2.0-fold ULN.
• Any condition contraindicating leukapheresis, lymphodepletion, low-dose IL-2, and/or IMA203/IMA203CD8 treatment
• Patients with active brain metastases
• Concurrent treatment in another clinical trial.
• For nivolumab treatment, patients must not have a history of severe immune-related toxicities, defined as any Grade 3 or 4 toxicities related to prior PD1/PD-L1 inhibitor therapy (e.g., atezolizumab, pembrolizumab or nivolumab etc.).

Other protocol defined inclusion/exclusion criteria could apply

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

375 participants in 12 patient groups

Dose Escalation A (closed to enrollment)

Experimental group

Description:

Dose escalation of IMA203

Treatment:

Biological: IMA203 Product

Device: IMADetect®

Extension Cohort A

Experimental group

Description:

IMA203 at RP2D

Treatment:

Biological: IMA203 Product

Device: IMADetect®

Extension Cohort B (closed to enrollment)

Experimental group

Description:

IMA203 at RP2D + nivolumab

Treatment:

Drug: Nivolumab

Biological: IMA203 Product

Extension Cohort AA

Experimental group

Description:

IMA203 at final RP2D (flat dose)

Treatment:

Biological: IMA203 product- flat dose

Device: IMADetect®

Uveal Melanoma

Experimental group

Description:

IMA203 at RP2D

Treatment:

Biological: IMA203 Product

Device: IMADetect®

Dose Escalation B

Experimental group

Description:

Dose escalation of IMA203CD8

Treatment:

Biological: IMA203CD8 Product

Device: IMADetect®

Extension Cohort C

Experimental group

Description:

IMA203CD8 at dose levels confirmed to be safe

Treatment:

Biological: IMA203CD8 Product

Device: IMADetect®

Extension Cohort D

Experimental group

Description:

IMA203CD8 at dose levels confirmed to be safe; without IL-2

Treatment:

Biological: IMA203CD8 Product

Device: IMADetect®

Ovarian

Experimental group

Description:

IMA203CD8 monotherapy at dose levels confirmed to be safe

Treatment:

Biological: IMA203CD8 Product

Device: IMADetect®

Endometrial

Experimental group

Description:

IMA203CD8 monotherapy at dose levels confirmed to be safe

Treatment:

Biological: IMA203CD8 Product

Device: IMADetect®

Head and Neck, Lung, and Triple Negative Breast Cancer

Experimental group

Description:

IMA203CD8 monotherapy at dose levels confirmed to be safe

Treatment:

Biological: IMA203CD8 Product

Device: IMADetect®

Rare Cancers

Experimental group

Description:

IMA203CD8 monotherapy at dose levels confirmed to be safe

Treatment:

Biological: IMA203CD8 Product

Device: IMADetect®